| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Pyxis Oncology, Inc. | Director | Stock Option (Right to Buy) | 36,979 | $36,239 | $0.9800 | 31 Mar 2025 | Direct |
| Xilio Therapeutics, Inc. | Director | Common Stock | 9,444 | $7,839 | $0.8300 | 21 Oct 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| PYXS | Pyxis Oncology, Inc. | 31 Mar 2025 | 1 | +$36,239 | 4 | Director | 02 Apr 2025, 09:03 |
| PYXS | Pyxis Oncology, Inc. | 26 Mar 2024 | 1 | $0 | 4 | Director | 28 Mar 2024, 16:32 |
| PYXS | Pyxis Oncology, Inc. | 24 Mar 2023 | 1 | $0 | 4 | Director | 28 Mar 2023, 16:43 |
| PYXS | Pyxis Oncology, Inc. | 11 Aug 2022 | 1 | $0 | 4 | Director | 15 Aug 2022, 17:44 |
| PYXS | Pyxis Oncology, Inc. | 11 Aug 2022 | 0 | $0 | 3 | Director | 15 Aug 2022, 17:31 |
| XLO | Xilio Therapeutics, Inc. | 21 Oct 2021 | 0 | $0 | 3 | Director | 21 Oct 2021, 20:41 |